Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price rose 9.4% during trading on Wednesday . The company traded as high as GBX 4.18 ($0.06) and last traded at GBX 3.94 ($0.05). Approximately 3,379,912 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 4,994,842 shares. The stock had previously closed at GBX 3.60 ($0.05).
Shield Therapeutics Price Performance
The company has a 50 day moving average of GBX 3.55 and a 200 day moving average of GBX 2.44. The stock has a market capitalization of £31.13 million, a price-to-earnings ratio of -90.00 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Trading Stocks: RSI and Why it’s Useful
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Dividend Payout Ratio Calculator
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
